@misc{10498/36540,
year = {2017},
url = {http://hdl.handle.net/10498/36540},
abstract = {Glucagonoma syndrome is a rare paraneoplastic syndrome characterized by elevated serum levels of glucagon, the presence of glucagonoma, and dermatological clinical findings such as necrolytic
migratory erythema (NME) (John & Schwartz, 2016; Luber, Ackerman, Culpepper, Buschmann, & Koep, 2016). The main challenge
associated with the diagnosis of glucagonoma syndrome is that at
diagnosis, metastasis has already occurred in more than 50% of
cases. However, this tumor tends to exhibit slow growth; median
survival is 3–7 years and patients have survived for up to 24 years
(John & Schwartz, 2016; Mendoza-Guil, Hern andez-Jurado, Burkhardt, Linares, & Naranjo, 2005). Furthermore, NME significantly
affects patients’ quality of life and is characteristically resistant to
treatment (Thomaidou, Nahmias, Gilead, Zlotogorski, & Ramot,
2016). In this sense, additional knowledge regarding effective drugs
for treating persistent NME is needed.},
publisher = {Wiley},
title = {Necrolytic migratory erythema associated with glucagonoma treated successfully with cyclosporine},
doi = {10.1111/DTH.12498},
author = {Jiménez Gallo, David and Ossorio García, Lidia and De la Varga Martínez, Raquel and Arjona Aguilera, Cintia and Linares Barrios, Mario Dionisio},
}